IMDX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$8.25median target· current $3.58 (+130.4%)4 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
48 articles · sorted by datePage 1 of 3 · 48 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-1.340.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$117.2MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 87.06
- P/S (TTM)
- 70.15
- EV/EBITDA
- -1.25
Profitability & growth
- ROE (TTM)
- -23603.0%
- Operating margin
- -3815.0%
- Revenue growth YoY
- -53.9%
- Dividend yield
- —
- Beta
- 1.80
Last earnings
Aug 10, 2026 · Estimate $-0.23 · Reported $-0.23
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Insight Molecular Diagnostics Inc.
Company profileOncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.
Classification
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 2 INTERNATIONAL PLAZA DR., NASHVILLE, TN
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$117.2M
Shares outstanding$32.7M
52W high$8.51
52W low$2.42
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent